Correlation Engine 2.0
Clear Search sequence regions

  • citalopram (9)
  • female (1)
  • humans (1)
  • patients (2)
  • women (4)
  • Sizes of these terms reflect their relevance to your search.

    This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women. A parallel prospective randomized clinical trial was conducted in 91 postmenopausal women with a total score on the Menopause Rating Scale (MRS) ≥ 17 and with the clinical diagnosis of VSM and GSM. Patients were randomly assigned to receive citalopram (n = 49) or fluoxetine (n = 42). Follow-up was carried out at 3 and 6 months. The citalopram group experienced a significant improvement compared to the fluoxetine group in the MRS total score (p < 0.01), as well as in the psychological (p < 0.001) and somatic (p < 0.0001) domains at 3 and 6 months of follow-up. After 6 months of follow-up, the group that received citalopram decreased the relative risk (RR) to present VMS symptoms (RR = 0.30, CI 0.19-0.5, p = 0.0001), depressed mood (RR = 0.31, CI 0.15-0.6, p = 0.0002), irritability (RR = 0.40, CI 0.22-0.73, p = 0.002), anxiety (RR = 0.30, CI 0.13-0.69, p = 0.003), physical and mental exhaustion (RR = 0.35, CI 0.18-0.67, p = 0.001), sexual problems (RR = 0.18, CI 0.06-0.48, p = 0.0001), vaginal dryness (RR = 0.34, CI 0.14-0.80, p = 0.01), and urinary problems (RR = 0.36, CI 0.14-0.92, p = 0.043). We conclude that citalopram tends to improve VSM and GSM symptoms in postmenopausal Mexican women. Thus, we recommend the daily use of citalopram 20 mg. However, further studies will be required to support the results of the present work. These should include a larger number of patients and a placebo group. This clinical trial was retrospectively registered by the United States National Library of Medicine in the www. gov database on 04/20/2022. The given test Registration Number is NCT05346445. © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.


    Alan Rios-Espinosa, Magdalena Cruz-Luna, Carolina Garmendia-Gallardo, Merle Yasmin Hernández-Castañón, Verónica Yazmin Hernández-Hernández, Paula Mariana Sánchez-Tinoco, Alma Bajonero-Domínguez, Jael Adrián Vergara Lope-Núñez, Marco Antonio Álvarez-Pérez, José Luis González-Quiroz, Patricia Loranca-Moreno, Juan Moises Ocampo-Godínez. Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. Archives of gynecology and obstetrics. 2022 Dec;306(6):2035-2045

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35997971

    View Full Text